【上证医药】中国生物制药收购礼新医药,肿瘤创新领域再添核心竞争力——医药生物行业周报(20250714-0718)

上海证券研究
21 Jul

1报告摘要中国生物制药宣布收购礼新医药。2025年7月15日,中国生物制药发布公告,将以约5亿美元100%收购礼新医药科技(上海)有限公司。收购交易完成后,礼新医药将成为中国生物制药全资子公司。2024年8月,中国生物制药以1.42亿元人民币参与礼新医药的C1轮融资,取得礼新4.91%的股权,并就LM-108及潜在的多个创新双特异性抗体或ADC,在中国大陆地区与之达成战略合作。礼新医药研发成果瞩目...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10